Market Overview
North America's nuclear medicine market covers diagnostic procedures using PET and SPECT imaging, alongside radionuclide therapies that deliver targeted radiation treatment. The market comprises radiopharmaceuticals, imaging equipment, and related services supplied to hospitals, imaging centers, and research facilities. The United States leads regional demand, with Canada contributing a smaller but steady share through its publicly funded healthcare system, while Mexico's market remains nascent but shows investment-driven potential.
- •Market valued at approximately $5.4 billion in 2025 with a projected 14.0% compound annual growth rate
- •U.S. accounts for the dominant share due to advanced healthcare infrastructure and high adoption of new technologies
- •Market spans both diagnostic radiopharmaceuticals (imaging agents) and therapeutic radiopharmaceuticals (treatment compounds)
Growth Drivers
Rising cancer incidence across North America is a central growth engine, as nuclear medicine enables early detection, staging, and increasingly, targeted therapy. The aging population amplifies demand for cardiac and neurological imaging, where nuclear procedures provide unique functional insights that complement anatomical imaging. Continued innovation in radiopharmaceuticals, including new diagnostic tracers and targeted radionuclide therapies, expands the clinical utility of nuclear medicine.
- •Increasing prevalence of cancer and cardiovascular disease driving diagnostic and therapeutic demand
- •Aging demographic trends boosting demand for cardiac and neurodegenerative disease imaging
- •FDA approvals of novel radiopharmaceuticals expanding treatment options and market access
Segmentation and Regional Analysis
The market is segmented by product into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals, with diagnostic applications holding the larger volume share. By procedure type, the market includes SPECT imaging, PET imaging, and targeted radionuclide therapies, each serving oncology, cardiology, and neurology applications. Geographically, the United States represents the overwhelming majority of North American market activity, supported by higher healthcare spending and faster regulatory approval timelines, while Canada and Mexico present smaller but evolving opportunities.
- •Diagnostic segment includes widely used isotopes such as Technetium-99m and Fluorine-18 FDG
- •Therapeutic radiopharmaceuticals are the fastest-growing sub-segment, driven by radioligand therapies
- •United States dominates the regional landscape, with Canada and Mexico representing emerging growth markets
Trends and Outlook
What are the recent trends and outlook?
Theranostics, which pairs diagnostic imaging with targeted radiation therapy, is emerging as a transformative trend that promises to expand both the clinical value and market size of nuclear medicine. Supply chain security for critical medical isotopes, particularly Molybdenum-99 and emerging theranostic isotopes, remains a strategic priority following periodic global shortages. Through 2035, the market is expected to benefit from continued FDA approvals, expanding clinical indications for existing radiopharmaceuticals, and growing adoption of PET imaging in neurology and cardiology.
- •Theranostics and radioligand therapies represent the highest-growth application area, with multiple therapies in late-stage development
- •Supply chain diversification initiatives aim to secure domestic and allied-nation production of critical medical isotopes
- •Regulatory advancements and new product launches anticipated to broaden indications and drive sustained growth
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.